S
Sreyashi Basu
Researcher at University of Texas MD Anderson Cancer Center
Publications - 79
Citations - 7394
Sreyashi Basu is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Immune system & Nivolumab. The author has an hindex of 28, co-authored 64 publications receiving 6288 citations. Previous affiliations of Sreyashi Basu include University of Connecticut Health Center & University of Connecticut.
Papers
More filters
Journal ArticleDOI
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway
TL;DR: It is reported here that heat shock proteins (HSP), the most abundant and conserved mammalian molecules, constitute such an internal signal that provides a unified mechanism for response to internal and external stimuli.
Journal ArticleDOI
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.
TL;DR: It is shown here that complexes of peptides with heat shock proteins hsp90, calreticulin, and hsp70 are also taken up by macrophages and dendritic cells and re-presented by MHC class I molecules.
Journal ArticleDOI
Heat Shock Protein–Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity
Nathalie E. Blachere,Zihai Li,Rajiv Y. Chandawarkar,Ryuichiro Suto,Navdeep S. Jaikaria,Sreyashi Basu,Heiichiro Udono,Praniod K. Srivastava +7 more
TL;DR: It is demonstrated that HSPs are CD8+ T cell response–eliciting adjuvants that are immunologically active, as tested by their ability to elicit antitumor immunity and specificCD8+ cytolytic T lymphocyte response.
Journal ArticleDOI
Heat Shock Proteins Come of Age: Primitive Functions Acquire New Roles in an Adaptive World
TL;DR: It is conceivable that in a less polymorphic era, when adaptive immune response was but a distant gleam in the evolutionary eye, the interaction of HSPs with macrophage-like cells, leading to stimulation of the macrophages to secrete IL-1 and other messengers, was the primary “innate” defense mechanism.
Journal ArticleDOI
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Naval Daver,Guillermo Garcia-Manero,Sreyashi Basu,Prajwal Boddu,Mansour Alfayez,Jorge E. Cortes,Marina Konopleva,Farhad Ravandi-Kashani,Elias Jabbour,Tapan M. Kadia,Graciela M. Nogueras-Gonzalez,Jing Ning,Naveen Pemmaraju,Courtney D. DiNardo,Michael Andreeff,Sherry Pierce,Tauna Gordon,Steven M. Kornblau,Wilmer Flores,Zainab Al-Hamal,Carlos E. Bueso-Ramos,Jeffrey L. Jorgensen,Keyur P. Patel,Jorge Blando,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +26 more
TL;DR: Azacitidine in combination with nivolumab therapy produced an encouraging response rate and overall survival in patients with R/R AML, particularly in HMA-naïve and salvage 1 patients.